|
Summary
March 2008, Vol. 13, No. 1, Pages 53-62
, DOI 10.1517/14728214.13.1.53
Emerging therapies for fibromyalgiaJacob N Ablin 1 MD & Dan Buskila †2 MD1Tel Aviv Sourasky Medical Center, Rheumatology Institute, Tel Aviv, Israel † Author for correspondenceBackground: Fibromyalgia syndrome (FMS) is a disorder characterized by widespread pain, tenderness, and fatigue. High prevalence marks the syndrome which is considered to reflect altered central pain processing. Fibromyalgia syndrome runs a chronic, non-progressive course, extracting high price owing to impaired quality of life, restricted vocational capacity, and increased health care utilization. Objective: To review current and emerging trends in the treatment of FMS. Methods: A rigorous search of published literature, abstract presentations, and industry provided data was performed. Results/conclusion: The recent FDA approval of pregabalin as a first specific medication for FMS may herald a new era for the development of medications with higher specificity and efficacy for this hitherto frustrating condition.
| Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes Bo AhrénSummary
| Full Text
| PDF (326 KB)
| PDF Plus (377 KB)
|
Add to Favorites
| Related | |
|
|
|